Distribution Of Standard-Of-Care Antituberculosis Drugs In Cynomolgus Macaque Lungs

Although the study evaluated only one animal per time point due to ethical considerations, it revealed notable variability in drug exposure — most strikingly in animal ID I050CAB at 6h15, which showed significantly higher levels than others. This finding underscores the importance of accounting for individual variability in PBPK modeling, especially in antituberculosis research involving limited non-human primate (NHP) populations.

The study also generated valuable reference data on HRZE distribution in the lungs of cynomolgus macaques, contributing to a better understanding of pharmacokinetics and supporting the optimization of dosing strategies for anti-TB therapies. Furthermore, it lays the groundwork for future investigations into drug concentrations within infected lesions, advancing PK/PD modeling in tuberculosis research.

Explore the study's findings further by downloading the poster below.